Skip to main content
OpenTrials
Completed

NCT Number: NCT03967964

Pharmacokinetics of a Novel Vaginal Delivery System for Testosterone and Dehydroepiandrosterone (DHEA)

This study was performed to determine the pharmacokinetic parameters of vaginal rings that contain DHEA, testosterone, or combinations of both androgens, in comparison to the oral administration of DHEA and the transdermal administration of testosterone.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pharmacokinetics Hormone Deficiency

Age range

40 year–60 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 1

Primary location

Instituto de Investigación Materno Infantil (IDIMI) - Maternidad Hospital San Borja (HCSBA)

Santiago, Chile

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women between 40 to 60 years old.
  • Postmenopausal with spontaneous amenorrhea of 1 year or more, regardless of follicle stimulating hormone (FSH) levels; or amenorrhea of 6 to 12 months, in which the postmenopausal state will be confirmed with a FSH level of 0.040 international units per milliliter or higher.
  • Body Mass Index between 19 and 30.
  • Intact uterus.
  • Not having received hormone therapy in the month prior to selection.
  • Adequate veins to conduct serial blood samplings.
  • Recent Pap smear (not more than 12 months), with a result negative for malignant neoplastic cells, and that contains sufficient endocervical cells for analysis. If the Pap smear was performed more than 12 months ago or cannot be verified through clinical documentation, it must be repeated during the selection process.
  • Normal mammogram, BI.RADS I or II (American College of Radiology), within the last year. If the mammogram was performed more than 12 months ago or cannot be verified through clinical documentation, it must be repeated during the selection process.
  • That provide written informed consent.

Exclusion criteria

  • Use at randomization of phenytoin, barbiturates, primidone, carbamazepine, rifampin, griseofulvin, ketoconazole, lipid-lowering agents.
  • History of diseases such as coronary heart disease, breast cancer, uterine cancer, and/or chronic hepatic disease.
  • Unconscious volunteers, severely ill, or with mental disability.
  • Allergy and hypersensitivity to DHEA and/or testosterone.
  • Untreated or uncontrolled hypertension, with systolic pressure above 140 mm Hg or diastolic pressure above 90 mm Hg.
  • Current participation in other research at the moment of the screening visit, or having concluded their participation in a previous research in less than 30 days since their last visit.
  • Pregnant or lactating women; pregnancy must be confirmed with a urine positive human chorionic gonadotropin (HCG) test during screening.
  • History of vein thrombosis (deep vein thrombosis, pulmonary embolism).
  • History of arterial thrombosis (myocardial infarction) or prodromic conditions (e.g. transient ischemic attack, angina pectoris).
  • History of stroke.
  • History of migraine with focal neurological manifestations.
  • History of hepatic tumor (benign or malignant).
  • History of clinical atherosclerosis in first grade relatives (parents, siblings, sons [men less than 55 years old and women less than 65 years old]).
  • Smoking (5 or more cigarettes a day).
  • Diabetes mellitus that will be ruled out at screening if fasting glucose is less than 100 mg/dL or between 100 and 125 mg/dL, with Oral Glucose Tolerance Test that rules out diabetes. Diabetes will be confirmed with blood glucose equal to or above 200 mg/dL or 2 fasting glucose tests equal to or above 126 mg/dL.
  • High density lipopolysaccharide (HDL)-cholesterol below 35 mg/dL.

Treatment and study plan

Dehydroepiandrosterone 2.2 g

Drug

Vaginal ring with 2.2 grams DHEA.

Dehydroepiandrosterone 1.5 g/Testosterone 25 mg

Drug

Vaginal ring with DHEA 1.5 grams/Testosterone 25 mg.

Testosterone

Drug

Vaginal ring with 35 mg testosterone.

Testosterone Topical Gel

Drug

Gel containing 1% testosterone.

Other names: ActiserPump®

Dehydroepiandrosterone Oral Capsule

Drug

Capsule containing 25 mg DHEA

Primary outcomes

  1. Testosterone: Area under the serum concentration time curve (AUC0-72)

    Time frame: Pre-dose and from 30 minutes after administration of the assigned treatment to 72 hours

    Serum testosterone was measured pre-dose and at 30 minutes, at 1 hour, 2, 4, 6, 8, 24, 48, and 72 hours after vaginal ring insertion, the transdermal application of the testosterone gel, or after taking DHEA capsules. The AUC0-72 was calculated.

  2. DHEA: Area under the serum concentration time curve (AUC0-72)

    Time frame: Pre-dose and from 30 minutes after administration of the assigned treatment to 72 hours

    Serum DHEA were measured pre-dose and at 30 minutes, at 1 hour, 2, 4, 6, 8, 24, 48, and 72 hours after vaginal ring insertion, the transdermal application of the testosterone gel, or after taking DHEA capsules. The AUC0-72 was calculated.

  3. Testosterone: Average serum concentration 0-24 hours

    Time frame: Pre-dose and from 30 minutes after administration of the assigned treatment to 24 hours

    Serum testosterone was measured pre-dose and at 30 minutes, at 1 hour, 2, 4, 6, 8, 24, 48, and 72 hours after vaginal ring insertion, the transdermal application of the testosterone gel, or after taking DHEA capsules. The average serum concentration achieved in the first 24 hours after administration of the assigned treatment was calculated.

  4. DHEA: Average serum concentration 0-24 hours

    Time frame: Pre-dose and from 30 minutes after administration of the assigned treatment to 24 hours

    Serum DHEA was measured pre-dose and at 30 minutes, at 1 hour, 2, 4, 6, 8, 24, 48, and 72 hours after vaginal ring insertion, the transdermal application of the testosterone gel, or after taking DHEA capsules. The average serum concentration achieved in the first 24 hours after administration of the assigned treatment was calculated.

  5. Testosterone: Maximum serum concentration (Cmax)

    Time frame: Pre-dose and from 30 minutes after administration of the assigned treatment to 72 hours

    Serum testosterone was measured pre-dose and at 30 minutes, at 1 hour, 2, 4, 6, 8, 24, 48, and 72 hours after vaginal ring insertion, the transdermal application of the testosterone gel, or after taking DHEA capsules. Cmax was calculated.

  6. DHEA: Maximum serum concentration (Cmax)

    Time frame: Pre-dose and from 30 minutes after administration of the assigned treatment to 72 hours

    Serum DHEA was measured pre-dose and at 30 minutes, at 1 hour, 2, 4, 6, 8, 24, 48, and 72 hours after vaginal ring insertion, the transdermal application of the testosterone gel, or after taking DHEA capsules. Cmax was calculated.

  7. Testosterone: Time to achieve maximum serum concentration (tmax)

    Time frame: pre-dose and from 30 minutes after administration of the assigned treatment to 72 hours

    Serum testosterone was measured pre-dose and at 30 minutes, at 1 hour, 2, 4, 6, 8, 24, 48, and 72 hours after vaginal ring insertion, the transdermal application of the testosterone gel, or after taking DHEA capsules. Tmax was calculated.

  8. DHEA: Time to achieve maximum serum concentration (tmax)

    Time frame: pre-dose and from 30 minutes after administration of the assigned treatment to 72 hours

    Serum DHEA was measured pre-dose and at 30 minutes, at 1 hour, 2, 4, 6, 8, 24, 48, and 72 hours after vaginal ring insertion, the transdermal application of the testosterone gel, or after taking DHEA capsules. Tmax was calculated.

Sponsors and collaborators

Lead sponsor

Laboratorios Andromaco S.A.

Industry

Registry information

Official study title

Prospective, Randomized, Open-label and Comparative Study to Determine the Pharmacokinetic Parameters of Vaginal Rings That Contain DHEA, Testosterone, or the Combination of Both Androgens, in Comparison With Oral Administration of DHEA and Transdermal Administration of Testosterone, in Postmenopausal Women

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
May 30, 2019
Registry last updated
May 30, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.